Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- XFOR
- Price
- 0.20
- Stock movement down
- -0.01 (-2.48%)
- Company name
- X4 Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 34.93M
- Ent value
- 56.06M
- Price/Sales
- 8.35
- Price/Book
- 0.59
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -49.91%
- 1 year return
- -83.42%
- 3 year return
- -51.72%
- 5 year return
- -53.38%
- 10 year return
- -
Last updated: 2025-04-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
XFOR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 8.35 |
| Price to Book | 0.59 |
| EV to Sales | 13.40 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 170.55M |
| EPS (TTM) | -0.08 |
| FCF per share (TTM) | -0.63 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.18M |
| Gross profit (TTM) | 3.56M |
| Operating income (TTM) | -25.89M |
| Net income (TTM) | -16.76M |
| EPS (TTM) | -0.08 |
| EPS (1y forward) | -0.59 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 85.20% |
| Operating margin (TTM) | -618.81% |
| Profit margin (TTM) | -400.65% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 97.41M |
| Net receivables | -4.48M |
| Total current assets | 142.97M |
| Goodwill | 17.35M |
| Intangible assets | 10.19M |
| Property, plant and equipment | 7.11M |
| Total assets | 178.16M |
| Accounts payable | 8.58M |
| Short/Current long term debt | 78.20M |
| Total current liabilities | 29.26M |
| Total liabilities | 118.54M |
| Shareholder's equity | 59.62M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -125.65M |
| Capital expenditures (TTM) | 320.00K |
| Free cash flow (TTM) | -125.97M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -28.11% |
| Return on Assets | -9.41% |
| Return on Invested Capital | -12.32% |
| Cash Return on Invested Capital | -92.58% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.22 |
| Daily high | 0.22 |
| Daily low | 0.20 |
| Daily Volume | 1.40M |
| All-time high | 156.18 |
| 1y analyst estimate | 2.68 |
| Beta | 0.39 |
| EPS (TTM) | -0.08 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 May 2025 |
Downside potential
Loading...
Downside potential data
| XFOR | S&P500 | |
| Current price drop from All-time high | -99.87% | -12.04% |
| Highest price drop | -99.87% | -56.47% |
| Date of highest drop | 14 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -90.24% | -11.07% |
| Avg time to new high | 169 days | 12 days |
| Max time to new high | 1778 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
34.93M
Marketcap category
Small-cap
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Employees
127
Website
Investor relations
-
SEC filings
CEO
Paula S. Ragan
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page